Related Experiment Video

Updated: Aug 7, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

siRNA-mediated antitumorigenesis for drug target validation and therapeutics

Patrick Y Lu1, Frank Y Xie, Martin C Woodle

  • 1Intradigm Corporation, 12115 K Parklawn Drive, Rockville, MD 20852, USA. patricklu@intradigm.com

Current Opinion in Molecular Therapeutics
|July 23, 2003
PubMed

Insights

Small interfering RNA (siRNA) is a powerful tool for gene silencing in biomedical research, especially in cancer. This review explores siRNA

Area of Science:

  • Biomedical Research
  • Cancer Genomics
  • RNA Interference Therapeutics

Background:

  • Small interfering RNA (siRNA) is crucial for gene knockdown, requiring target mRNA accessibility, cellular delivery, and potent inhibition.
  • siRNA applications are rapidly expanding across biomedical research, with significant advancements in cancer studies.

Purpose of the Study:

  • To review the application and efficacy of siRNA in cancer research.
  • To evaluate siRNA's role in validating cancer genes and developing therapeutic strategies.
  • To compare siRNA efficiency with other gene silencing methods like antisense oligonucleotides.

Main Methods:

  • Review of existing literature on siRNA in cancer research.
  • Analysis of functional validation studies in cell culture and animal models.
  • Assessment of various siRNA delivery systems and their effectiveness.

Main Results:

  • siRNA has been successfully used to functionally validate tumorigenic genes in preclinical cancer models.
  • Various effective siRNA delivery systems have been developed for both local and systemic administration.
  • siRNA demonstrates potential as a therapeutic agent for cancer, pending optimized delivery systems.

Conclusions:

  • siRNA is a valuable functional genomic tool in cancer research.
  • Optimized delivery systems are key to unlocking siRNA's therapeutic potential in oncology.
  • siRNA represents a promising novel therapeutic modality for cancer treatment.

More Related Videos

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...